# RadNet, Inc. (RDNT)

> Source: Nexqual · https://nexqual.com/RDNT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, RadNet, Inc. (RDNT), nexqual.com/RDNT" · informational, not investment advice.

**Price:** USD 70.41 (+1.81% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 69.16 · day 69.08–70.81 · 52w 50.82–85.84 · market cap $5.54B · NGM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $2.27B, net income -$21.1M (-0.9% margin) (SEC filings).
- 2 of 80 tracked superinvestors hold RDNT (13F, Q2 2026): 0 new, 1 added, 0 reduced, 1 unchanged.
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 94.63 (range 79–105).
- Total return with dividends: 1Y -9.0% vs S&P 500 +18.1%; 5Y +144.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD 0.22, revenue estimate $639M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.32B | $1.43B | $1.62B | $1.83B | $2.04B | $2.27B |
| Operating income | $82.6M | $46.4M | $98.7M | $105M | $62.0M | $70.8M |
| Net income | $24.7M | $10.7M | $3.0M | $2.8M | -$18.7M | -$21.1M |
| EPS (diluted) | $0.46 | $0.17 | $0.05 | $0.04 | -$0.25 | — |
| Operating margin | 6.3% | 3.2% | 6.1% | 5.7% | 3.0% | 3.1% |
| Net margin | 1.9% | 0.7% | 0.2% | 0.2% | -0.9% | -0.9% |
| Revenue growth | +22.7% | +8.7% | +13.0% | +13.2% | +11.5% | — |
| Cash + short-term investments | $135M | $128M | $343M | $740M | $767M | — |
| Total debt | $755M | $852M | $830M | $1.02B | $1.09B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 2.4x · EV/EBITDA 25.4x · EV/Sales 2.7x · P/B 5.1x · Earnings yield -0.38% · Net debt $606M · EV $6.15B
P/E at fiscal year-ends: Dec 2024 1869.5x, Dec 2023 738.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
2 of 80 tracked investors hold RDNT. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Mairs & Power | Mairs & Power Funds | 0.08% | $8.2M | Unchanged |
| First Eagle Investment | First Eagle Investment Management | 0.02% | $12.0M | Added +107.2% |

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 94.63 (low 79, high 105).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-28 | Barclays | Target raised | Overweight | $65 → $79 |
| 2026-08-11 | Truist Securities | Target raised | Buy | $90 → $94 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -9.0% | +144.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -9.1% | +19.5% |
| Volatility (annualized) | 42.1% | 42.5% |
| Max drawdown | -38.6% (Nov 2025→Jun 2026) | -52.0% (Nov 2021→Nov 2022) |

## Peers (Diagnostics & Research)
SHC (Sotera Health Company) USD 18.07 -0.77% · GRAL (GRAIL, Inc.) USD 135.46 -3.48% · BLLN (BillionToOne, Inc.) USD 102.73 +8.78% · ADPT (Adaptive Biotechnologies Corpor) USD 25.58 +1.19% · VCYT (Veracyte, Inc.) USD 44.39 +2.97% · CDNA (CareDx, Inc.) USD 66.68 +1.90%

## More
Full page: https://nexqual.com/RDNT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt